Angela B. Smith, MD, MS, discusses how her institution has adjusted how it conducts clinical trials in the COVID-19 era.
In this video, Angela B. Smith, MD, MS, explains how the COVID-19 pandemic has affected patient recruitment for and conducting of clinical trials at her institution. Smith is vice chair of academic affairs, director of urologic oncology, and associate professor of urology at UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.